CD34, RAB20, PU.1 and GFI1 mRNA expression in myelodysplastic syndrome

International Journal of Laboratory Hematology

Volumn 31, Issue 3, 2009, Pages 344-351

  Huh, H J ^b   Chae, S L ^b   Lee, M ^c   Hong, K S ^c   Mun, Y C ^c   Seong, C M ^c   Chung, W S ^c   Huh, J W ^a,c  

^a Mokdong Hospital   (South Korea)

^b Dongguk University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

Author keywords

CD34; GFI1; Myelodysplastic syndrome; PU.1; RAB20; Real time RT PCR

Indexed keywords

CD34 ANTIBODY; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW; CANCER RISK; CD34 GENE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GFI1 GENE; HUMAN; INFANT; KARYOTYPE; MALE; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; ONCOGENE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PU.1 GENE; RAB20 GENE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; ANTIGENS, CD34; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROTO-ONCOGENE PROTEINS; RAB GTP-BINDING PROTEINS; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 65349112453     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2008.01056.x     Document Type: Article

References (35)

1. Amillet J.M., Ferbus D., Real F.X., Antony C., Muleris M., Gress T.M. Goubin G. (2006) Characterization of human Rab20 overexpressed in exocrine pancreatic carcinoma. Human Pathology 37, 256 263.
2. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R. Sultan C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal Haematology 51, 189 199.
3. Cook W.D., McCaw B.J., Herring C., John D.L., Foote S.J., Nutt S.L. Adams J.M. (2004) PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood 104, 3437 3444.
4. Duan Z. Horwitz M. (2005) Gfi-1 takes center stage in hematopoietic stem cells. Trends in Molecular Medicine 11, 49 52.
5. Fuchigami K., Mori H., Matsuo T., Iwanaga M., Nagai K., Kuriyama K. Tomonaga M. (2000) Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. Leukemia Research 24, 163 174.
6. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G. Bennett J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079 2088.
7. Hock H. Orkin S.H. (2006) Zinc-finger transcription factor Gfi-1: versatile regulator of lymphocytes, neutrophils and hematopoietic stem cells. Current Opinion in Hematology 13, 1 6.
8. Hock H., Hamblen M.J., Rooke H.M., Traver D., Bronson R.T., Cameron S. Orkin S.H. (2003) Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity 18, 109 120.
9. Hock H., Hamblen M.J., Rooke H.M., Schindler J.W., Saleque S., Fujiwara Y. Orkin S.H. (2004) Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature 431, 1002 1007.
10. Iwasaki H., Somoza C., Shigematsu H., Duprez E.A., Iwasaki-Arai J., Mizuno S., Arinobu Y., Geary K., Zhang P., Dayaram T., Fenyus M.L., Elf S., Chan S., Kastner P., Huettner C.S., Murray R., Tenen D.G. Akashi K. (2005) Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 106, 1590 1600.
11. Karsunky H., Zeng H., Schmidt T., Zevnik B., Kluge R., Schmid K.W., Duhrsen U. Moroy T. (2002) Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1. Nature Genetics 30, 295 300.
12. Keung Y.K., Pettenati M.J., Cruz J.M., Powell B.L., Woodruff R.D. Buss D.H. (2001) Bone marrow cytogenetic abnormalities of aplastic anemia. American Journal of Hematology 66, 167 171.
13. Livak K.J. Schmittgen T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402 408.
14. Maciejewski J.P. Selleri C. (2004) Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leukaemia & Lymphoma 45, 433 440.
15. Maciejewski J.P., Risitano A., Sloand E.M., Nunez O. Young N.S. (2002) Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 99, 3129 3135.
16. Marisavljevic D., Cemerikic V., Rolovic Z., Boskovic D. Colovic M. (2005) Hypocellular myelodysplastic syndromes: clinical and biological significance. Medical Oncology 22, 169 175.
17. Matsui W.H., Brodsky R.A., Smith B.D., Borowitz M.J. Jones R.J. (2006) Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 20, 458 462.
18. McKercher S.R., Torbett B.E., Anderson K.L., Henkel G.W., Vestal D.J., Baribault H., Klemsz M., Feeney A.J., Wu G.E., Paige C.J. Maki R.A. (1996) Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO Journal 15, 5647 5658.
19. Metcalf D., Dakic A., Mifsud S., Di Rago L., Wu L. Nutt S. (2006) Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 103, 1486 1491.
20. Mikhailova N., Sessarego M., Fugazza G., Caimo A., De Filippi S., van Lint M.T., Bregante S., Valeriani A., Mordini N., Lamparelli T., Gualandi F., Occhini D. Bacigalupo A. (1996) Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica 81, 418 422.
21. Miyazato A., Ueno S., Ohmine K., Ueda M., Yoshida K., Yamashita Y., Kaneko T., Mori M., Kirito K., Toshima M., Nakamura Y., Saito K., Kano Y., Furusawa S., Ozawa K. Mano H. (2001) Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 98, 422 427.
22. Orazi A., Albitar M., Heerema N.A., Haskins S. Neiman R.S. (1997) Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. American Journal of Clinical Pathology 107, 268 274.
23. Oriani A., Annaloro C., Soligo D., Pozzoli E., Cortelezzi A. Lambertenghi Deliliers G. (1996) Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes. British Journal Haematology 92, 360 364.
24. Otawa M., Kawanishi Y., Iwase O., Shoji N., Miyazawa K. Ohyashiki K. (2000) Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia. Leukemia Research 24, 359 366.
25. Pellagatti A., Esoof N., Watkins F., Langford C.F., Vetrie D., Campbell L.J., Fidler C., Cavenagh J.D., Eagleton H., Gordon P., Woodcock B., Pushkaran B., Kwan M., Wainscoat J.S. Boultwood J. (2004) Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. British Journal Haematology 125, 576 583.
26. Pereira-Leal J.B. Seabra M.C. (2001) Evolution of the Rab family of small GTP-binding proteins. Journal of Molecular Biology 313, 889 901.
27. Person R.E., Li F.Q., Duan Z., Benson K.F., Wechsler J., Papadaki H.A., Eliopoulos G., Kaufman C., Bertolone S.J., Nakamoto B., Papayannopoulou T., Grimes H.L. Horwitz M. (2003) Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nature Genetics 34, 308 312.
28. Ribeiro E., Matarraz Sudon S., de Santiago M., Lima C.S., Metze K., Giralt M., Saad S.T., de Matos A.O. Lorand-Metze I. (2006) Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leukemia Research 30, 9 16.
29. Sole F., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Luno E., Prieto F., Granada I., Hernandez J.M., Cigudosa J.C., Diez J.L., Bureo E., Marques M.L., Arranz E., Rios R., Martinez Climent J.A., Vallespi T., Florensa L. Woessner S. (2000) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. British Journal Haematology 108, 346 356.
30. Sole F., Luno E., Sanzo C., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Cigudosa J.C., Milla F., Ribera J.M., Bureo E., Marquez M.L., Arranz E. Florensa L. (2005) Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90, 1168 1178.
31. Sternberg A., Killick S., Littlewood T., Hatton C., Peniket A., Seidl T., Soneji S., Leach J., Bowen D., Chapman C., Standen G., Massey E., Robinson L., Vadher B., Kaczmarski R., Janmohammed R., Clipsham K., Carr A. Vyas P. (2005) Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 106, 2982 2991.
32. Timeus F., Crescenzio N., Doria A., Foglia L., Linari A., Giaccone M., Pastore G., di Montezemolo L.C., Ramenghi U. Saracco P. (2005) Flow cytometric evaluation of circulating CD34+ cell counts and apoptotic rate in children with acquired aplastic anemia and myelodysplasia. Experimental Hematology 33, 597 604.
33. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A. Speleman F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3, 1 12. Research 0034.
34. Zeng H., Yucel R., Kosan C., Klein-Hitpass L. Moroy T. (2004a) Transcription factor Gfi1 regulates self-renewal and engraftment of hematopoietic stem cells. EMBO Journal 23, 4116 4125.
35. Zeng W., Chen G., Kajigaya S., Nunez O., Charrow A., Billings E.M. Young N.S. (2004b) Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood 103, 325 332.